Peptide therapy: what does this term mean and why do the scientific evidence differ so much?

„Peptide therapy” is a broad term encompassing interventions that utilize substances with a peptide structure. It does not mean a standardized treatment method, a single mechanism of action, a single field of medicine, or a single level of scientific evidence.

Depending on the context, this term can refer to:

• a registered prescription drug;
• an experimental relationship being studied as part of a clinical trial;
• a peptide that is part of a more complex therapeutic system;
• or a widely advertised commercial service referred to as „peptide therapy”.

Therefore, the assessment of any claim regarding „peptide therapy” requires first establishing what exactly the substance, the finished product, the indication, the formulation, and the regulatory status are in question, and what evidence supports the proposed use.[1]

Some peptide medicines have extensive data from controlled human studies and specific indications approved by regulatory authorities.

Others are still in the research phase.

Others are discussed primarily based on laboratory experiments, animal studies, small exploratory studies involving humans, mechanistic hypotheses, user opinions, or commercial claims.

These situations should not be combined into a single overall verdict regarding whether „peptide therapy works”.

From a scientific point of view, the correct question is not:

Does peptide therapy work?

It is much better to ask:

What exactly is the peptide intervention, in what formulation, in what indication, in what population, compared with what and based on what evidence?

This distinction is crucial because peptides constitute a very broad chemical and pharmacological category, rather than a single therapeutic class with universal clinical efficacy.

The peptide intervention studied in oncology cannot be evaluated based on data regarding the metabolic drug.

A peptide studied for one endocrine effect does not automatically rule out evidence regarding other effects.

Cosmetic serums containing peptides do not inherit evidence regarding a peptide drug administered by injection simply because both products contain molecules referred to as peptides.

In this article, we explain the differences between chemical identity, biological mechanism, formulation, clinical studies, regulatory authorization, and commercial claims. We also show how to evaluate evidence without assuming that results regarding one peptide automatically apply to another.

This is an educational review of the evidence, not a guide on the selection of treatment, prescribing, dosing, preparation, or administration of peptides.

The regulatory examples in the article refer to specific jurisdictions, and their status was reviewed on September 20, 2026.

What exactly is „peptide therapy”?

The chemical category does not define the method of treatment

Peptides are molecules composed of amino acid residues linked by peptide bonds.

However, mere membership in this chemical category tells relatively little about how a given substance behaves biologically.

Among other things, the following may be relevant:

• the sequence of amino acids;
• chain length;
• spatial structure;
• electrical load;
• chemical modifications;
• affinity to receptors;
• metabolic stability;
• susceptibility to enzymatic decomposition;
• formulation;
• the route of delivery;
• interactions with other molecules.

Two substances can therefore be peptides and at the same time perform completely different biological functions.

One peptide can interact with a receptor associated with metabolism.

Another one may be related to a receptor present on the cancer cells.

Another one can act as a signaling molecule.

Another one can be a component of a cosmetic product.

Another may remain an experimental molecule without a determined clinical application.

Common term „peptide” This does not mean that two substances:

• they bind to the same receptor;
• they reach the same tissue;
• they elicit the same biological response;
• they have similar adverse reaction profiles;
• or have a comparable level of clinical evidence.

If you want to first learn the basic structure, nomenclature, and classification of peptides, see: Peptides – what they are, how they work, and how they are classified.

Peptide drugs are designed for specific biological tasks.

The development of drugs utilizes a vast variety of peptide structures.

Depending on the specific molecule, the peptide intervention can:

• to imitate the natural signaling process or modify it;
• activate the receptor;
• to inhibit a receptor or a specific interaction;
• influence the biological pathway;
• enable molecular targeting;
• to form an element of a more complex therapeutic structure.

Reviews concerning the development of peptide drugs describe both the potential associated with these molecules as well as the problems regarding, among other things, stability, delivery, degradation, pharmacokinetics, production, and reaching the appropriate biological target.[1]

This is precisely why the interesting peptide sequence does not automatically become an effective drug.

What questions should be asked before evaluating „peptide therapy”?

Any meaningful assessment should begin with a few basic questions:

What exactly is the molecule?

What formulation?

What indication?

What is the population?

Which comparator?

What is the endpoint?

What regulatory jurisdiction?

Without this information, the term „peptide therapy” is too broad to reliably assess its effectiveness, safety, or regulatory status.

Four questions to determine the fundamental identity of the intervention

These questions are worth answering before considering whether the proposed biological mechanism sounds credible.

First, it is necessary to determine whether we are actually dealing with a sufficiently well-defined intervention that can be evaluated.

„Therapy” does not always mean the same thing

The very word Therapy it can be a source of misunderstandings.

In science, medicine, cosmetology, commercial services, and the wellness sector, it can be used in various meanings.

In a clinical trial, therapy usually means a precisely defined intervention applied according to a documented protocol.

Researchers define, among other things:

• the intervention under review;
• the population of participants;
• comparator;
• duration of the study;
• terminal points;
• the way of analyzing the results.

In the commercial language, the term „peptide therapy” can be much broader.

The service advertised in this way can, for example, combine:

• consultations;
• a change in lifestyle;
• modification of nutrition;
• supplements;
• monitoring;
• one or more substances related to peptides.

If several elements change simultaneously, the observed improvement cannot be automatically attributed to the peptide.

Is a positive user experience proof of action?

It is not the same as a causal proof.

A person may actually feel better after starting a multi-elemental program.

The experience itself may be real, but the cause of the improvement remains uncertain.

Possible explanations include:

• the action of the peptide;
• the influence of another program element;
• changes in sleep or eating habits;
• change in physical activity;
• parallel treatment;
• the effect of expectations;
• natural variations in the symptoms;
• several factors acting simultaneously.

Controlled studies are designed precisely so that at least some of these alternative explanations can be separated from each other.

The term „peptide” also occurs outside of medical treatment.

Peptides are also often found in cosmetics and hair products.

A product for hair advertised as a „peptide treatment” can, for example, be a conditioner or a cosmetic treatment intended to affect the appearance or properties of the hair fiber.

This is not evidence for a systemic peptide drug.

Similarly, a controlled clinical study of a peptide product does not confirm the effectiveness of a cosmetic product for hair or skin.

The search results for „peptide therapy” therefore require proper classification first.

You can find more about the cosmetic applications of peptides in hair care here: Hair peptides: care, scalp products and scientific evidence.

Peptides and oligonucleotides are different categories

Peptides and oligonucleotides are often discussed together in the context of pharmaceutical development, production technologies, scientific conferences, and industry reports.

However, they are not chemically interchangeable.

Peptides are made up of amino acid residues.

Oligonucleotides are formed from nucleotide units.

Some of the problems associated with their development may be similar, but the structure and biological behavior of these molecules are different.

Does the presence of a peptide at a scientific conference prove its effectiveness?

No.

The conference program can include peptides, proteins, oligonucleotides, and other advanced therapies within a single scientific event.

This simply means that these topics are being discussed together.

The conference presentation can concern:

• Preliminary laboratory results;
• analytical methods;
• production technology;
• early clinical results;
• unpublished data;
• updates of the ongoing study;
• completed study.

The actual data determine what conclusions can be drawn, and not the mere fact of presenting at a conference.

Approved drugs and experimental compounds

Authorization applies to a specific product and use

Regulatory authorities do not approve „peptides” as a single category.

Authorisation applies to specific medicinal products and the specific circumstances of their use.

Depending on the jurisdiction, it may include, among other things:

• the specific active substance;
• formulation;
• indication;
• the patient population;
• production standard;
• product information;
• the route of administration.

The approval of a single peptide drug does not therefore mean approval of:

• another peptide;
• in another formulation;
• another indication;
• a product from another manufacturer;
• a service unrelated to it that is advertised as „peptide therapy”.

Examples of authorization of specific products

The European Medicines Agency lists the specific uses of the Wegovy product containing semaglutide and the Mounjaro product containing tirzepatide. [2] [3]

This represents an example of a regulated context for specific products.

It does not, however, confirm the existence of a single, scientifically verified category referred to as:

„metabolic peptide therapy”.

It also does not mean that every product advertised using the names semaglutide or tirzepatide has the same status.

Does the approval of a drug mean that it is suitable for everyone?

No.

Regulatory authorization does not mean that the drug:

• does not cause adverse effects;
• it is suitable for everyone;
• it works identically in all cases;
• it is approved for every possible application.

The appropriate context is determined by the current information regarding the specific product, including indications, restrictions, precautions, and other regulatory information.

„Experimental” means a research status

If a substance or a specific use thereof is experimental, this means that it remains the subject of scientific research.

This does not automatically mean that the substance is ineffective.

It also does not mean that its effectiveness has already been established.

The most precise conclusion is:

Important questions are still the subject of research.

Clinical development proceeds in stages

Studies involving humans do not constitute a single stage.

Early studies can analyze:

• pharmacokinetics;
• exhibition;
• tolerance;
• Preliminary biological effects;
• dosage ranges within the research protocol.

Later studies may assess:

• effectiveness;
• comparison with placebo or other treatment;
• the repeatability of the effect;
• larger populations;
• longer observation period.

Even promising early results do not guarantee later approval.

„Promising” does not mean „proven”

Early studies of some experimental compounds may show interesting or significant effects.

This may justify further research.

However, it does not eliminate the need:

• research confirming;
• a broader assessment of safety;
• longer observation;
• evaluations of the production process;
• regulatory review;
• risk-benefit analysis.

Retatrutyd clearly shows this difference.

In a published phase 2 retatrudine study, a reduction in body weight was described in a specific study population.[4]

This means that retatrutide has been studied in humans and measurable results were observed under these conditions.

However, this does not automatically mean that an experimental treatment becomes widely accepted as a treatment.

In the current FDA communication, retatrutide and cagrilintide are listed as substances that are not components of drugs approved by the FDA.[5]

This is information related to the US regulatory jurisdiction.

It should not be turned into a universal statement regarding the status of the product worldwide.

Does Phase 2 testing mean that the peptide is almost approved?

Not necessarily.

Phase 2 study may provide important data on efficacy and safety, but further clinical development and regulatory assessment may still be necessary.

Some interventions with promising early results do not subsequently confirm sufficient benefits or an acceptable safety profile.

The phase 2 retatrudine study therefore constitutes evidence regarding a specific phase of clinical trials, and not a guarantee of future authorization.[4]

Clinical data and authorization are two different facts

The substance may have:

data from human studies, but without regulatory approval.

On the other hand, an approved drug may still be studied for:

• new indications;
• other populations;
• alternative formulations;
• long-term results.

Research and regulatory status should therefore be reported separately.

Off-label, prescription medication and unapproved products

Off-label does not mean the same as an unapproved product

Off-label use refers to an approved drug used outside of the specific elements of its approved product information.

An unapproved product does not have such authorization.

These are two different situations.

The pharmaceutical recipe is another separate category

The preparation of a product as part of compounding should also be distinguished from the standard approval of an industrially produced drug.

The FDA explains that prescription drugs do not undergo the same safety, efficacy, and quality evaluation before being placed on the market as products approved by the FDA.[5]

Therefore, a prescription drug should not be labeled as „FDA approved” just because its label lists a component that is also present in an approved drug.

The same active substance name does not mean equivalence of products.

Two products can use the same active substance name, but differ in terms of:

• formulation;
• excipients;
• the method of production;
• stability;
• quality control;
• packaging;
• regulatory status.

The mere coincidence of the component name does not confirm equivalence.

Research materials constitute another category

The product sold as a material for laboratory testing is not the same as a medicinal product.

Terms such as:

• „research use only”;
• „laboratory use”;
• „for research purposes only”

they do not confirm their suitability for human use.

Similarly, a certificate confirming a certain level of chemical purity is not evidence of clinical authorization.

Is „research use only” a form of medical authorization?

No.

The labeling of a product as intended for research does not constitute consent for therapeutic use or confirmation of its suitability for human administration.

It defines the research context, not clinical authorization.

The current status of the medicinal product should be checked in the relevant regulatory sources and applied to the specific finished product.

The regulatory status should have a date.

The product status may change.

The application can be:

• complex;
• evaluated;
• approved;
• rejected;
• retired;
• extended with a new indication;
• modified for the new formulation.

Therefore, when describing the regulatory status, it is worth mentioning:

• jurisdiction;
• product;
• indication if it is relevant;
• the date of verification.

Does FDA or EMA approval apply everywhere?

No.

The regulatory status is linked to a specific jurisdiction.

The FDA status applies to the United States, and the EMA information relates to the European regulatory context.

Other countries may have their own regulatory authorities, procedures, deadlines, and approved indications.

Therefore, information about authorization should not be presented as universal without indicating the jurisdiction and the date.

The historical publication does not confirm today's status

A clinical study published a few years ago shows what researchers were evaluating at that time.

In itself, it does not confirm the current regulatory status.

Current information about authorization should be checked separately in the regulator’s sources.

The scientific publication and regulatory document answer various questions.

Studies on cells, animals and humans

Laboratory studies show biological possibilities

Cellular experiments can test whether a substance affects:

• receptor;
• enzyme;
• signal path;
• expression of genes;
• the phenotype of the cell;
• other biological processes.

Such studies can be very valuable.

They help to understand the mechanism and determine which hypotheses are worth investigating further.

Does the cellular study show that the peptide works in humans?

No.

Cells found in laboratory conditions do not replicate the entire human body.

Cellular experiments usually cannot determine:

• absorption;
• systemic distribution;
• metabolism;
• elimination;
• clinically relevant exposure;
• long-term adverse effects;
• total clinical benefit.

Biological activity in the laboratory is therefore not the same as a proven therapeutic effect.

Animal studies add information about the entire organism

Animal models allow us to study elements that cannot be reproduced in isolated cells.

It is possible to analyze, among other things:

• distribution;
• physiology;
• metabolism;
• effect on organs;
• behavior;
• toxicity;
• results related to the disease modeled.

However, the problem of transferring the results to humans remains.

Why can't the results of animal studies be directly applied to humans?

Differences may include:

• the biology of the species;
• location of receptors;
• metabolism;
• model of the disease;
• level of exposure;
• evaluated final points;
• the duration of the experiment.

The results of the animal study can therefore justify further studies without confirmation of clinical efficacy in humans.

Do longevity studies in animals confirm anti-aging therapy in humans?

No.

Studies of longevity in animals can generate important hypotheses regarding the biology of aging.

However, species differences, life span, exposure, disease patterns, and experimental conditions limit the direct transfer of such results to humans.

The claim that a specific peptide extends a person's healthy life requires relevant data on humans, and not merely changes in survival in animals or markers related to aging.

A credible mechanism is the beginning, not the end of the evaluation

The biological mechanism can increase the credibility of the hypothesis.

However, it does not replace clinical data.

Reasoning:

The peptide affects the X pathway → the X pathway is associated with the result Y → therefore the peptide causes the result Y in humans

contains an unconfirmed phase until the actual clinical outcome is properly examined.

Does the known biological mechanism confirm the therapeutic claim?

No.

The mechanism explains why the effect can be biologically possible.

It does not automatically show whether sufficient amount of the substance reaches its target or whether the effect is large enough to be of clinical significance.[1]

Mechanistic and clinical evidence can complement each other, but they address different questions.

Evidence involving humans also has varying strength.

Case descriptions

The case description documents an observation involving one person or a very small number of people.

It might help to identify:

• an unusual effect;
• potential adverse effects;
• a hypothesis worth further investigation.

However, it usually does not allow for a reliable determination of the causal relationship.

Studies without a control group

An uncontrolled study can reveal interesting patterns.

However, it is more difficult to separate the impact of the intervention from:

• natural changes;
• regression to the mean;
• parallel treatment;
• changes in behavior;
• expectations;
• effects of selection.

Observational studies

Observational studies can involve larger populations and analyze the relationships that occur in real-world conditions.

However, groups may differ even before the intervention begins.

The factors that influence why a person receives a particular treatment can also influence the outcome.

Randomized controlled studies

Randomization helps to separate the measured and unmeasured differences between the groups according to the planned allocation process.

This may strengthen the causal interpretation.

However, this does not mean that:

randomized trial = automatically the final proof.

They still have meaning:

• the number of samples;
• examined population;
• comparator;
• blindness, when possible;
• selection of endpoints;
• the observation period;
• compliance with the protocol;
• missing data;
• statistical analysis;
• the possibility of relating the result to the current statement.

Is every study involving humans stronger than a study on animals?

The mere fact of people's participation is not enough.

A well-designed study involving humans is usually more directly related to a clinical claim concerning humans.

However, an uncontrolled anecdote involving one person can provide much weaker causal evidence than a carefully conducted experiment.

Studies such as SURMOUNT-1 are more informative because they specify the population, comparator, endpoints, and the study design.[7]

Therefore, it is necessary to assess both the significance of the evidence for a specific question and the methodological quality.

Repetition increases certainty

One study can provide important information.

Similar results obtained independently in subsequent studies increase the certainty that the observed effect is repeatable.

This is especially important when:

• The first study was small;
• the result was unexpected;
• many endpoints were analyzed;
• there were commercial interests involved.

The result of the test belongs to a specific indication.

NETTER-1 shows how precise evidence can be

The NETTER-1 study evaluated lutet-177 in individuals with advanced, progressive neuroendocrine tumors of the middle intestine showing somatostatin receptor expression.[6]

The clinical context concerned, among other things, the experience of progression-free survival in a very specific oncology population.

The study therefore provides evidence regarding:

• a specific therapeutic design;
• the specific type of cancer;
• selected receptor status;
• a defined endpoint.

It does not confirm the unrelated claims regarding:

• general wellness;
• „anti-aging”;
• sports regeneration;
• anti-aging;
• other diseases.

The peptide can only be one component of a more complex therapy

The Lutet-177 dataset also shows why trying to reduce every intervention to a „peptide” can be misleading.

The therapeutic properties depend on more than just the peptide sequence itself.

The directional element and the radioactive component are important for understanding:

• mechanism;
• exposure;
• effectiveness;
• risks.

Therefore, the term „peptide therapy” alone for the entire intervention removes clinically important information.

SURMOUNT-1 answers a completely different question

SURMOUNT-1 evaluated tirzepatide for changes in body weight in adults with obesity or overweight and at least one weight-related complication, without diabetes. [7]

The evidence relates to:

• specific medication;
• metabolic indications;
• of a given population;
• defined endpoints;
• specific period of study.

NETTER-1 and SURMOUNT-1 concern peptide-related therapies.

However, they are not evidence of the existence of a single universal „peptide therapy”.

Can one peptide treat many unrelated diseases?

One molecule can have several biological effects and can be studied in various indications.

However, any clinical claim requires appropriate evidence.

A positive result in one population cannot be automatically transferred to another disease or another endpoint.

SELECT is a good example: cardiovascular outcomes were assessed directly, instead of inferring them solely based on previous weight-related outcomes.[8]

Therefore, the individual proposed applications must be analyzed separately.

The endpoint does not mean all possible benefits

Biological activity and clinical benefit are different things

A change in the biomarker can confirm the biological activity.

It does not automatically mean that:

• the person feels better;
• functioning improves;
• the risk of complications decreases;
• life expectancy is increasing.

Similarly, the result reported by the patient may be clinically important, but it requires appropriate, validated measurement and a proper comparator.

One clinical result does not automatically confirm another

A study showing weight reduction does not automatically lead to a reduction in cardiovascular events.

These are separate research questions.

The SELECT study separately evaluated cardiovascular outcomes associated with semaglutide in people with known cardiovascular disease and overweight or obesity without diabetes. [8]

It is the population and the endpoint of the study that determine the scope of possible conclusions.

The same principle applies to other claims

Claims regarding:

• pain;
• of sleep;
• cognitive functions;
• regeneration;
• the functioning of the muscles;
• resistance;
• metabolic health;
• longevity

they require appropriate measurement methods.

The change in the molecular pathway associated with aging does not prove that the peptide prolongs human life.

Changing the inflammatory marker does not automatically mean an improvement in symptoms or the course of the disease.

Can the improvement of a biomarker be considered a clinical benefit?

Not automatically.

If the test showed a change in a biomarker, it is safest to describe the change in that biomarker.

Transformation of a laboratory or surrogate result into a statement about:

• improvement of symptoms;
• quality of life;
• the prevention of the disease;
• surviving

requires appropriate evidence linking this marker with a real clinical outcome.

The SELECT example shows why cardiovascular outcomes required direct testing instead of inferring them solely based on weight loss.[8]

The formulation and the route of administration are part of the intervention

Delivery of the peptide is important

The development of peptide drugs may encounter problems related to:

• enzymatic degradation;
• absorption;
• crossing biological barriers;
• stability;
• elimination;
• by reaching the appropriate tissue. [1]

Therefore, the formulation can determine whether the molecule will achieve the appropriate exposure.

Oral semaglutide shows the importance of formulation

The development of the oral form of semaglutide illustrates this principle well.

The technology of delivery and the clinical trial program were integral parts of demonstrating the efficacy of this formulation.[9]

The existence of a validated oral peptide product does not, however, mean that:

• Peptides as a group are well absorbed upon ingestion;
• any capsule containing a peptide will behave similarly;
• An untested oral preparation will replicate the exposure of the approved drug.

Are the oral and injectable forms interchangeable?

Not automatically.

Different routes of administration can lead to very different levels of exposure.

Oral delivery of peptides may require specially developed formulation technology, an example of which is the development of oral semaglutide.[9]

Evidence regarding one route of administration should not be automatically transferred to another.

The same active substance name does not confirm identical pharmacokinetics, exposure, efficacy, or product retention.

Do the data regarding the peptide in the injection confirm the effect of the topical product?

No.

Local and injectable delivery create completely different exposure conditions.

The skin forms an important barrier for many molecules, whereas injection bypasses part of these barriers.

Therefore, the local product requires evidence relating to the local formulation and the appropriate endpoint.

The mere similarity of the name of a peptide does not imply equivalent exposure or clinical activity.

Identity, purity, quantity and clinical effectiveness are different issues

Chemical identity

The identity answers the question:

What molecule is present in the sample?

Appropriate analytical techniques can help determine this.

Purity

Purity describes the relative composition of the sample according to a specific analytical method.

The percentage value provided therefore requires information:

• which method was used;
• what was detected;
• What exactly does the given percentage mean?.

Quantity

The quantity answers the question of how much of the active substance is actually present in the sample.

Confirmation of correct identity does not automatically mean correct quantity.

Quality is a concept broader than purity

In the case of finished medicinal products, the quality assessment may also include:

• sterility, if required;
• pollution;
• degradation products;
• stability;
• packaging;
• control of the production process;
• the repeatability between batches.

A single cleanliness score does not answer all of these questions.

Does the analysis certificate confirm the effectiveness of the therapy?

No.

The Certificate of Analysis, or COA, can provide useful analytical data regarding a specific sample.

However, he does not confirm:

• clinical effectiveness;
• therapeutic equivalence;
• regulatory authorization;
• suitability for a specific medical application.

Can COA replace regulatory quality controls?

No.

The certificate can describe the results of specific analyses performed for a given sample.

The quality of a medicinal product may, however, additionally include identity, quantity, impurities, stability, sterility, reproducibility of production, packaging and other parameters.

The COA should therefore be interpreted in accordance with what was actually examined.

High purity does not transfer clinical evidence

High-purity research material does not automatically include evidence regarding the regulated finished medicinal product.

The intervention clinically examined involves more than just the sequence itself:

• the active substance;
• formulation;
• production;
• the route of administration;
• product properties;
• conditions of the study.

Clinical evidence therefore concerns a specific intervention, and not merely the name of the molecule.

Combinations require their own proofs

Several tested ingredients do not automatically form a tested combination

A package containing several peptides or several different interventions creates a new research question.

Evidence regarding each component separately does not automatically mean that their combination is:

• more effective;
• safer;
• synergistic;
• free from interaction.

The study of combinations requires a proper design

A credible claim regarding a combination may require information about:

• the actually applied combination;
• biological justification;
• formulation;
• comparator;
• final points;
• interactions;
• adverse effects.

Multielement packages make it difficult to assign an effect

If the participants simultaneously change:

• medicines;
• diet;
• physical activity;
• supplementation;
• dream;
• exposure to peptides,

it is difficult to determine which element was responsible for the observed change.

The same principle applies to customer opinions and history.

A positive experience can be authentic, but it does not automatically determine the contribution of each component of the program.

Does a higher number of peptides mean stronger evidence?

No.

The mere combination of several substances does not increase the quality of the evidence.

It may, however, make it more difficult to assess:

• exposure;
• interaction;
• adverse effects;
• the responsibility of individual components for the effect.

A credible claim regarding combinations requires research into the combination itself.

The same evidence should not be counted twice

One study can lead to many publications

One clinical study can lead to the creation of:

• the main publication;
• analysis of subgroups;
• long-term studies;
• publications concerning secondary endpoints;
• post-hoc analysis;
• corrections;
• conference abstracts;
• scientific correspondence.

Counting each publication as an independent study can artificially inflate the apparent size of the evidence base.

Does the large number of publications concerning the same peptide mean a large database of evidence?

Not necessarily.

Several publications may come from a single study or from overlapping populations of participants.

In the review it is worth distinguishing between:

• the main publication of the study;
• analysis of subgroups;
• study extended;
• secondary analysis;
• a completely independent study.

The number of citations is therefore not the same thing as the number of independent studies.

The independence of the participants is important

When reviewing the evidence, it is worth checking whether different publications use:

• the same participants;
• partially overlapping groups;
• completely independent cohorts.

Ten publications do not necessarily mean ten independent studies.

Does the meta-analysis prove that the peptide works?

Not automatically.

Meta-analysis can increase statistical precision when sufficiently similar studies are available.

However, it does not address the fundamental methodological problems common to source-based research.

If the included studies:

• they have weak control groups;
• they measure very different results;
• they are subject to a significant risk of error;
• apply to populations that do not fit the current claim,

The combined result may still be difficult to interpret.

Therefore, the quality and adequacy of the source studies matter, not the mere fact of conducting a meta-analysis.

Authorisation, clinical evidence and commercial availability are different things

These concepts are often combined in online discussions about peptides.

It is worth clearly separating them.

Does commercial availability mean that the peptide has been clinically verified?

No.

The substance can be sold, advertised, discussed on the internet, or offered as a service without the possession of controlled clinical data regarding the claimed use.

Availability, product quality, regulatory status, and clinical evidence must be verified separately.

How should claims regarding peptide therapy be evaluated?

It is best to start with a specific claim and only then look for the evidence that actually supports it.

This is a method of evaluating evidence, not a list used to independently choose whether to use interventions.

The results of the study should be read in conjunction with its limitations.

A good scientific description should indicate:

• what was studied;
• what was observed;
• with which the comparison was made;
• what was the magnitude of the effect;
• what important restrictions remain.

The more spectacular the result, the more important it is to preserve information about the population and the conditions under which it was obtained.

The absence of evidence does not mean the absence of action.

These two situations require a different language.

If an appropriate study has not been conducted, the effect may remain:

unconfirmed.

However, if a well-designed study directly evaluated the claim and did not show a significant effect, we are dealing with a different type of information.

The lack of evidence regarding a specific peptide should not be supplemented by studies concerning other unrelated peptides.

„Unproven” does not mean „impossible”

Scientific uncertainty should remain uncertainty.

An unproven claim should not be presented as confirmed.

It should not be automatically presented as having been overthrown either, unless appropriate research has shown otherwise.

Opinions, conference presentations and registration of research

Opinions can describe an experience, but they do not establish the cause.

Reviews of clinics can provide information about:

• communication;
• customer service;
• organization of visits;
• the perceived quality of care;
• personal experiences.

However, they usually cannot determine the causal therapeutic effect.

Why does a testimonial not replace an examination?

User reviews are usually not controlled:

• natural changes in health status;
• parallel interventions;
• expectations;
• selective reporting;
• regression to the mean.

Therefore, they constitute a different category of evidence than controlled clinical trials.

Conference presentations require context

The results presented at conferences can be scientifically valuable.

A short abstract or presentation may, however, not include:

• complete methodology;
• complete data on adverse reactions;
• details of the statistical analysis;
• all information about subgroups.

Therefore, it is worth indicating the status of the publication.

Does the registration of the study mean that the peptide is effective?

No.

Registration increases transparency and shows that a study has been planned or started.

However, he does not confirm that:

• the study has been completed;
• the main endpoint has been reached;
• the intervention was effective;
• The results were favorable.

The results should be evaluated separately.

Hierarchy of evidence in assessing claims regarding peptides

The following diagram helps to organize the information. However, it does not mean that simply moving to a „higher” level automatically guarantees the high quality of a particular study.

Level 1: chemical and analytical evidence

Questions:

• Has the identity of the molecule been correctly determined?
• What is its purity?
• Is it stable?
• Can it be reliably identified?

These are chemical information, not evidence of clinical effectiveness.

Level 2: laboratory evidence of mechanistic principles

Questions:

• Does the molecule relate to the proposed target?
• Does it affect the expected path?
• Can the result be replicated in appropriate cellular models?

Such data increase the biological credibility of the hypothesis.

Level 3: animal studies

Questions:

• Does the effect appear throughout the body?
• What is the exposure associated with it?
• What physiological effects are observed?

Transferring the results to humans remains uncertain.

Level 4: early human studies

Questions:

• What kind of exposure occurs in humans?
• What signs of tolerance are emerging?
• Are there any preliminary signs of the expected effect?

Such results may justify further clinical development.

Level 5: Controlled clinical evidence

Questions:

• Does intervention work better than an appropriate comparator?
• How big is the effect?
• What side effects occur?
• What population was studied?

These are more direct evidence regarding the clinical claim.

Level 6: confirmatory studies and independent repeat studies

Larger or independent studies allow to assess whether the earlier results are repeatable and sufficiently stable.

Level 7: Regulatory authorization for a specific application

Regulatory authorization means the evaluation of a specific product for a specific indication in a specific jurisdiction.

It does not change the entire category of peptides into one approved therapy.

These levels should not be mixed together.

If the claim is based solely on a laboratory experiment, it should be described as laboratory evidence.

The result of the animal study should be labeled as pre-clinical.

Research involving humans should be presented according to the actual stage and results obtained.

The approved product should be described along with the relevant jurisdiction and indication.

Such terminology greatly facilitates the correct interpretation of information about peptides.

Frequently asked questions

Is peptide therapy a standardized treatment method?

No. The term encompasses many different substances and interventions with different biological targets, formulations, indications, and study histories. Peptide therapy used in oncology and a metabolic drug may belong to a broad category of peptides, but they relate to completely different diseases and biological pathways. [6] [7] Therefore, statements that „peptide therapy works” or „peptide therapy does not work” are too broad. The evaluation should be specific to the product, formulation, indication, population, comparator, and endpoint.

Does the approval of one peptide confirm the activity of other peptides?

No. Authorization and clinical evidence apply to specific products and uses, not to all substances with a peptide structure. The EMA information regarding semaglutide and tirzepatide well illustrates the product-specific nature of the regulatory status. [2] [3] Another peptide sequence, formulation, route of administration, or indication constitutes a separate research question. Therefore, data regarding a recognized drug cannot be used as evidence of the efficacy of the peptide not associated with it.

Is a naturally occurring peptide automatically safe as a therapy?

No. The natural presence of a given molecule in the body does not confirm the safety of its external administration. The biological effect may depend on the concentration, exposure, site of action, time, formulation, and molecular modifications.[1] From a scientific perspective, therefore, it is appropriate to assess the specific product and specific exposure, rather than assuming „natural = safe.”.

Does off-label mean the same thing as an unapproved peptide?

No. Off-label refers to an approved drug used outside the elements of its approved product information. An unapproved product does not have such authorization. Prescription drugs constitute another category, and the preparation of these within the framework of compounding does not mean approval by the FDA. [5] These categories should be distinguished because their regulatory status and quality control system may differ.

Does „clinically studied peptide” mean clinically proven therapy?

Not necessarily.

The term „clinically tested peptide” should lead to further questions:

• which peptide?
• What formulation?
• What kind of test?
• What population?
• What indication?
• Which comparator?
• what result?

The substance may indeed be studied in humans, but at the same time there may be no data confirming its use as currently advertised.

„Clinically studied” therefore describes the history of the research, not a universal clinical validation.

Is the selective peptide risk-free?

No.

Selectivity towards a specific biological target does not eliminate the possibility of adverse effects.

The desired pharmacological effect can occur simultaneously with adverse effects.

Therefore, in clinical trials, the safety and discontinuation of treatment are analyzed in parallel with efficacy.

In SURMOUNT-1, both weight-related outcomes and adverse events from the gastrointestinal tract were reported, as well as cases of discontinuation of participation. [7]

Do the evidence for one country mean approval of the product everywhere?

No.

The regulatory status depends on the jurisdiction.

The FDA, the EMA and regulatory authorities of other countries may make decisions at different times and for different indications.

Therefore, any statement of approval should indicate the specific jurisdiction and, where relevant, the date of verification.

What is the most important question when evaluating the claim regarding peptide therapy?

The most important question is:

What evidence relates specifically to this product and the exact application that is currently being claimed?

It is therefore necessary to determine:

• a specific intervention;
• formulation;
• the population;
• comparator;
• final point;
• regulatory status.

The existence of well-researched peptide drugs shows what a product-specific evidence base can look like, but does not confirm unrelated offers or products.[3][7]

What does a scientifically substantiated proposal look like?

The strongest proposal is concrete.

For example, it could sound like this:

The specific intervention resulted in a measurable change in a specific population under specific study conditions, compared to a specific comparator, and over a defined observation period.

Such a statement preserves the actual limits of the evidence.

A much weaker formulation would be:

„Peptide therapy works.”

The second sentence removes almost all the information needed to determine what was actually demonstrated.

Peptide therapy should therefore be understood as a broad field encompassing very different interventions.

Clinical certainty results from evidence regarding the specific product and indication, and not from the „peptide” label itself.

Limitations of the evaluation of „peptide therapy” as a single category

The first problem is category width.

Peptides encompass molecules that are chemically and pharmacologically very different. Treating them as a single therapeutic class hides important differences.

The second is Inappropriate indication.

A peptide may have strong evidence for one condition and very limited or no data for another.

The third is inappropriate wording.

Evidence relating to a single finished product should not be automatically transferred to another formulation containing the same active substance name.

The fourth is inappropriate path of entry.

The injection, the oral product, and the topical formulation can lead to a completely different exposure.

The fifth is inappropriate level of evidence.

Laboratory experiments, animal studies, early human studies, controlled clinical trials, and regulatory approval address other questions.

He is sixth. Regulatory mismatch.

Approval in one jurisdiction does not mean approval worldwide.

He is seventh. inappropriate product quality.

Purity, identity, quantity, sterility, stability, quality of production, and clinical efficacy are interrelated, but remain separate issues.

The eighth is Reproduction of publications.

Several articles may describe the same group of participants, which can make the evidence base appear larger than it actually is.

The ninth is commercial extrapolation.

Data on approved drugs can be rhetorically used to give the peptide services a scientific character unrelated to them.

The tenth is mechanistic extrapolation.

A credible biological pathway may justify the hypothesis, but it is not the same as the demonstrated clinical benefit.

Ultimately, the biggest limitation remains the lack of precision in defining „peptide therapy”.

This term should be the beginning of the evaluation of the evidence, not its final conclusion.

Summary

Peptide therapy is not a standardized treatment method.

It is a broad term encompassing very different peptide substances, formulations, medicinal products, experimental compounds, research materials, and commercial services.

Some peptide drugs have extensive data from controlled human studies and specific regulatory approvals.

Others have promising but still incomplete clinical data.

The latter are primarily supported by laboratory or animal studies.

In the case of some commercial claims, however, there may be a lack of evidence relating directly to the product offered and the claimed use.

Distinguishing between these situations is important because the evidence does not automatically apply to the entire category of peptides.

The approved metabolic peptide drug does not confirm the activity of the research peptide unrelated to it.

The oncological study does not prove anti-aging effects.

Phase 2 testing is not the same as regulatory approval.

The purity certificate does not confirm clinical effectiveness.

The laboratory mechanism does not demonstrate a therapeutic effect in humans.

Animal studies do not confirm the same result in humans.

The data regarding injections do not automatically confirm the unstudied oral or topical formulation.

And the user's opinion does not replace a controlled comparison.

The most reliable assessment of any claim therefore requires determining:

an exact molecule;

ready-made formulation;

the proposed indication;

studied population;

comparator;

the measured end point;

observation time;

adverse reactions and resignations;

the current regulatory status in the relevant jurisdiction;

and whether the available evidence actually relates to the product in question.

When these elements are clearly separated, it is much easier to scientifically evaluate information about peptides.

The useful conclusion therefore does not sound like this:

„peptide therapy works”

Nor:

„peptide therapy does not work”.

A more precise suggestion is:

any peptide intervention requires a separate evaluation that takes into account the specific product, indication, formulation, and the level and quality of the available evidence.

Disclaimer

The article is purely educational and scientifically informational in nature. It does not constitute medical advice, diagnosis, selection of treatment, instructions for prescribing, dosing, preparation, or administration of peptides. It is also not a recommendation to use any peptide, drug, prescription product, research material, supplement, cosmetic, or commercial service referred to as „peptide therapy.”.

Examples of approved and experimental products are presented solely to explain the differences between the levels of evidence and the regulatory status, and not to recommend treatment.

Regulatory status may change and may differ between different jurisdictions. Information regarding a specific medicinal product should always be obtained from the relevant regulatory authority for current data.

Individuals seeking information about a specific condition or approved medication should use the current product information from the appropriate regulatory authority and consult with a suitably qualified healthcare professional.

References

[1] Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: Current status and future directions. Drug Discovery Today, 20(1), 122–128. 10.1016/j.drudis.2014.10.003.

[2] European Medicines Agency. (n.d.). Wegovy: European public assessment report. Retrieved September 20, 2026, from Wegovy: European public assessment report.

[3] European Medicines Agency. (n.d.). Mounjaro: European public assessment report. Retrieved September 20, 2026, from Mounjaro: European public assessment report.

[4] Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators. (2023). Retatrutide, a triple-hormone-receptor agonist for obesity—A phase 2 trial. The New England Journal of Medicine, 389(6), 514–526. 10.1056/NEJMoa2301972.

[5] U.S. Food and Drug Administration. (n.d.). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved September 20, 2026, from FDA’s concerns with unapproved GLP-1 drugs used for weight loss.

[6] Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., Bushnell, D., O’Dorisio, T. M., Baum, R. P., Kulkarni, H. R., Caplin, M., Lebtahi, R., Hobday, T., Delpassand, E., Van Cutsem, E., … Investigators of the NETTER-1 Trial. (2017). Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. The New England Journal of Medicine, 376(2), 125–135. 10.1056/NEJMoa1607427.

[7] Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. 10.1056/NEJMoa2206038.

[8] Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., Ryan, D. H., & SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine, 389(24), 2221–2232. 10.1056/NEJMoa2307563.

[9] Lewis, A. L., McEntee, N., Holland, J., & Patel, A. (2022). Development and approval of Rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Delivery and Translational Research, 12(1), 1–6. 10.1007/s13346-021-01000-w.